Tvardi Therapeutics (TVRD) Tax Provisions (2013 - 2020)
Tvardi Therapeutics (TVRD) posted Tax Provisions of -$255000.0 for Q4 2020, down 93.18% sequentially from -$132000.0 in Q3 2020.
Tvardi Therapeutics (TVRD) Tax Provisions (2013 - 2020) Analysis & Trends
Tvardi Therapeutics has reported Tax Provisions for 8 years, with the latest figure at -$255000.0 in Q4 2020.
- Quarterly Tax Provisions changed N/A year-over-year to -$255000.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was -$255000.0 (up 76.52% YoY) and the FY2024 annual result came in at -$398000.0, changed N/A from the prior year.
- Tax Provisions fell to -$255000.0 in Q4 2020 per TVRD's latest filing, from -$132000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at -$2000.0 in Q2 2017 and troughed at -$650000.0 in Q3 2019.
- A 5-year average of -$147736.8 and a median of -$125000.0 in 2018 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2017 and 2018: Tax Provisions surged 97.47% in 2017, then tumbled 7500.0% in 2018.
- Over 5 years, Tax Provisions stood at -$189000.0 in 2016, then soared by 86.24% to -$26000.0 in 2017, then tumbled by 380.77% to -$125000.0 in 2018, then tumbled by 420.0% to -$650000.0 in 2019, then surged by 60.77% to -$255000.0 in 2020.
- According to Business Quant data, Tax Provisions over the past three periods registered -$255000.0, -$132000.0, and -$182000.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -255,000.00 |
| Sep 30, 2020 | -132,000.00 |
| Jun 30, 2020 | -182,000.00 |
| Mar 31, 2020 | -122,000.00 |
| Sep 30, 2019 | -650,000.00 |
| Jun 30, 2019 | -320,000.00 |
| Mar 31, 2019 | -85,000.00 |
| Dec 31, 2018 | -125,000.00 |
| Sep 30, 2018 | -66,000.00 |
| Jun 30, 2018 | -152,000.00 |
| Mar 31, 2018 | -46,000.00 |
| Dec 31, 2017 | -26,000.00 |
| Sep 30, 2017 | -145,000.00 |
| Jun 30, 2017 | -2,000.00 |
| Mar 31, 2017 | -31,000.00 |
| Dec 31, 2016 | -189,000.00 |
| Sep 30, 2016 | -55,000.00 |
| Jun 30, 2016 | -79,000.00 |
| Mar 31, 2016 | -145,000.00 |
| Dec 31, 2015 | -147,000.00 |